首页> 美国卫生研究院文献>Springer Open Choice >Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience
【2h】

Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience

机译:难治性或复发性霍奇金淋巴瘤患者采用统一改良的BEAM调理方案后自体造血干细胞移植的预后因素和长期结果:单中心经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the well-defined role of autologous haematopoietic stem cell transplantation (autoHCT) in the treatment of patients with relapsed or refractory Hodgkin lymphoma (HL), relapse remains the main cause of transplant failure. We retrospectively evaluated long-term outcome and prognostic factors affecting survival of 132 patients with refractory (n = 89) or relapsed HL (n = 43) treated with autoHCT following modified BEAM. With a median follow-up of 68 months, the 10-year overall survival (OS) and progression-free survival (PFS) were 76 and 66 %, respectively. The 10-year cumulative incidence of second malignancies was 7 %. In multivariate analysis, age ≥45 years, more than one salvage regimens and disease status at transplant worse than CR were factors predictive for poor OS. In relapsed HL, age at transplant, response duration (<12 vs. ≥12 months) and the number of salvage regimens were independent predictors for PFS. In the refractory setting, disease status at autoHCT and the number of salvage regimens impacted PFS. The number of risk factors was inversely correlated with PFS in both relapsed and refractory HL (p = 0.003 and <0.001, respectively). The median PFS for patients with >1 risk factor in the relapsed and refractory setting was 5 and 11 months, respectively, in comparison with the median PFS not reached for patients with 0–1 risk factor in both settings. We conclude that high proportion of patients with relapsed/refractory HL can be cured with autoHCT. However, the presence of two or more risk factors helps to identify poor prognosis patients who may benefit from novel treatment strategies.
机译:尽管自体造血干细胞移植(autoHCT)在复发或难治性霍奇金淋巴瘤(HL)患者的治疗中具有明确的作用,但复发仍然是移植失败的主要原因。我们回顾性评估了经改良BEAM治疗后用autoHCT治疗的132例难治性(n = 89)或复发性HL(n = 43)顽固性(132例)顽固性患者的远期结局和预后因素。平均随访68个月,其10年总生存率(OS)和无进展生存率(PFS)分别为76%和66%。第二年恶性肿瘤的10年累积发生率为7%。在多因素分析中,年龄≥45岁,不止一种挽救方案和移植时的疾病状况比CR差是可预测OS不良的因素。在复发性HL中,移植的年龄,反应时间(<12vs.≥12个月)和打捞方案的数量是PFS的独立预测因素。在难治性环境中,autoHCT的疾病状态和抢救方案的数量影响了PFS。复发和难治性HL的危险因素数量与PFS呈负相关(分别为p = 0.003和<0.001)。在复发和难治性环境中,危险因素> 1的患者的中位PFS分别为5个月和11个月,而在两种情况中,风险因素为0-1的患者未达到中位PFS。我们得出的结论是,autoHCT可以治愈高比例的复发/难治性HL患者。但是,存在两个或多个危险因素有助于确定预后较差的患者,这些患者可能会从新型治疗策略中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号